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Purpose. The aim of this study was to synthesize amino acid ester prodrugs of 5-fluoro-20-deoxyuridine
(floxuridine) to enhance intestinal absorption and resistance to glycosidic bond metabolism.
Methods. Amino acid ester prodrugs were synthesized and examined for their hydrolytic stability in
human plasma, in Caco-2 cell homogenates, and in the presence of thymidine phosphorylase. Glycyl-L-
sarcosine uptake inhibition and direct uptake studies with HeLa/PEPT1 cells [HeLa cells overexpressing
oligopeptide transporter (PEPT1)] were conducted to determine PEPT1-mediated transport and
compared with permeability of the prodrugs across Caco-2 monolayers.
Results. Isoleucyl prodrugs exhibited the highest chemical and enzymatic stability. The prodrugs
enhanced the stability of the glycosidic bond of floxuridine. Thymidine phosphorylase rapidly cleaved
floxuridine to 5-fluorouracil, whereas with the prodrugs no detectable glycosidic bond cleavage was
observed. The 50-L-isoleucyl and 50-L-valyl monoester prodrugs exhibited 8- and 19-fold PEPT1-
mediated uptake enhancement in HeLa/PEPT1 cells, respectively. Uptake enhancement in HeLa/
PEPT1 cells correlated highly with Caco-2 permeability for all prodrugs tested. Caco-2 permeability of
50-L-isoleucyl and 50-L-valyl prodrugs was 8- to 11-fold greater compared with floxuridine.
Conclusions. Amino acid ester prodrugs such as isoleucyl floxuridine that exhibit enhanced Caco-2
transport and slower rate of enzymatic activation to parent, and that are highly resistant to metabolism
by thymidine phosphorylase may improve oral delivery and therapeutic index of floxuridine.
KEY WORDS: Caco-2 permeability; floxuridine prodrugs; metabolism; PEPT1; thymidine
phosphorylase.
INTRODUCTION
Effective cancer chemotherapy depends on control of
drug levels at the tumor site. Many efforts have been made to
improve the delivery and therapeutic index of anticancer
drugs by chemically modifying the parent compound. Pro-
drugs of clinically effective cancer drugs such as 5-fluoro-20-
deoxyuridine (floxuridine) have been synthesized to improve
its physiochemical properties and to reduce toxicity. Thus, a
variety of alkyl ester prodrugs (1,2), phosphoramidate
prodrugs (3), photoactivated prodrugs (4), and amino acid
ester prodrugs (5,6) have been examined as potential
improvements. The objective of such approaches is not only
to enhance oral delivery but also to improve the metabolic
disposition of floxuridine after systemic delivery. In vitro
studies have demonstrated that the antiproliferative activity
of floxuridine was up to 5,000-fold greater than its metabo-
lite, 5-fluorouracil (5-FU), in several cancer cell lines (7).
Thus, the rapid phosphorolytic cleavage of floxuridine to 5-
FU in vitro and in vivo (8,9) represents a major obstacle in
delivering intact floxuridine to cells for enhanced cytotoxic
action. In addition, the degradation of floxuridine in rat
intestinal homogenates (1) and in humans after oral admin-
istration (10Y12) clearly suggest that floxuridine administered
orally would scarcely be absorbed as intact floxuridine.
A variety of chemical modifications have been shown to
render floxuridine more resistant to cleavage by pyrimidine
nucleoside phosphorylases (8). Aryl or long-chain alkyl
diesters of floxuridine were found to exhibit 100-fold higher
antitumor activity against L1210 leukemia cells after i.p.
administration to mice compared with floxuridine (13). It was
also clear from the studies in mice and rats that enhanced
resistance to enzymatic ester hydrolysis and to metabolism of
floxuridine was related to improved antitumor activity of the
prodrug. Thus, the maintenance of floxuridine plasma levels
after dosing of 30,50-dibenzoyl and 30,50-dipalmitoyl floxur-
idine suggested that protection from glycosidic bond desta-
bilization coupled with the slow release of intact floxuridine
from the prodrug leads to higher and more persistent plasma
levels compared to direct administration of floxuridine (1,13).
The release of active compound and its subsequent delivery
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to the target site can therefore be controlled by controlling
the rate of promoiety metabolism.
In addition to its conversion to a less active metabolite,
floxuridine exhibits low and erratic oral bioavailability and is
usually administered via intravenous infusion. Prodrug strat-
egies have also been used to improve oral absorption of
nucleoside analogs. Beauchamp et al. determined that some
amino acid esters of acyclovir, an antiviral drug with a low
oral bioavailability approximately 15% in humans (14), were
more effective for oral use (15). Thus, the oral bioavailability
of the L-valyl and L-isoleucyl esters of acyclovir in rats were
63 and 43%, respectively. Valacyclovir and valganciclovir,
two commercially marketed prodrugs of acyclovir and
ganciclovir, respectively, have been shown to be substrates
of oligopeptide transporters such as PEPT1 (16,17). PEPT1
has a wide substrate specificity and transports di- and
tripeptides as well as many peptidomemetic drugs (18) and
thus is an attractive transporter target for prodrug design.
Thus, prodrug approaches that incorporate strategies to
facilitate enhanced intestinal absorption and that minimize
floxuridine metabolism by thymidine phosphorylase to 5-FU
may allow enhanced floxuridine bioavailability and therapeu-
tic action. In this report, we describe the synthesis and
characterization of isoleucyl and leucyl ester prodrugs of
floxuridine designed for targeted delivery to the PEPT1
transporter. In addition to uptake and permeability studies,
the chemical and enzymatic stability of these prodrugs were
also evaluated to determine the effects of the amino acid
promoiety structure and esterification site on their activation
to the parent drug and on parent drug metabolism.
MATERIALS AND METHODS
Materials
Floxuridine (FUdR) was obtained from Lancaster
(Windham, NH, USA). The tert-butyloxycarbonyl (Boc)
protected amino acids, Boc-L-Ile and Boc-L-Leu, were
obtained from Calbiochem-Novabiochem (San Diego, CA,
USA). High-performance liquid chromatography (HPLC)-
grade acetonitrile was obtained from Fisher Scientific (St.
Louis, MO. USA). N,N-Dicyclohexylcarbodiimide, N,N-
dimethylformamide (DMF), N,N-dimethylaminopyridine, tri-
fluoroacetic acid (TFA), dichloromethane, and all other
reagents and solvents were purchased form Aldrich Chemical
Company (Milwaukee, WI, USA). Valacyclovir was a gift
from GlaxoSmithKline, Inc. (Research Triangle Park, NC,
USA). Cell culture reagents were obtained from Invitrogen
(Carlsbad, CA, USA) and cell culture supplies were obtained
from Corning (Corning, NY, USA) and Falcon (Lincoln
Park, NJ, USA). All chemicals were either analytical or
HPLC grade. Recombinant human thymidine phosphorylase
(TP) was purchased from Sigma (St. Louis, MO, USA).
Human plasma was obtained from the University of Michi-
gan Hospital Blood Bank (Ann Arbor, MI, USA) and stored
at j80-C until used.
FUdR Prodrug Synthesis
Isoleucyl and leucyl prodrugs of floxuridine were
synthesized in a manner similar to that reported for the valyl
prodrugs (5) (Fig. 1). Briefly, the Boc-protected amino acids
(Boc-L-Ile, Boc-L-Leu; 1 mmol), N,N-dicyclohexylcarbodii-
mide (1 mmol), and N,N-dimethylaminopyridine (0.1 mmol)
were allowed to react with FUdR (1 mmol) in 7 mL of dry
DMF for 24 h. The reaction progress was monitored by thin-
layer chromatography (ethyl acetate). The reaction mixture
was filtered and DMF removed under vacuum at 50Y55-C.
The residue was extracted with ethyl acetate (30 mL) and
washed with water (2  20 mL), saturated NaHCO3 (2  20
mL), and saturated NaCl (20 mL). The organic layer was
dried over MgSO4 and concentrated under vacuum. The
reaction yielded a mixture of 30-monoester, 50-monoester,
and 30,50-diester FUdR prodrugs. The three spots observed
on TLC were separated and purified using column chroma-
tography (ethyl acetate/hexanes, 1:1Y1:0). Fractions from
each spot were concentrated under vacuum separately. The
Boc group was cleaved by treating the residues with 4 mL of
TFA/dichloromethane/H2O (6:3:1). After 4 h the solvent was
removed and the residues were reconstituted with water and
lyophilized. The TFA salts of amino acid prodrugs of FUdR
were obtained as white fluffy solids.
HPLC was used to evaluate the purity of the prodrugs.
Prodrugs were between 96Y98% pure. These prodrugs were
easily separated from parent drug by HPLC. Electrospray
ionization mass spectra (ESI-MS) were obtained on a
Thermoquest LCQ electrospray ionization mass spectrome-
ter. The observed molecular weights of all prodrugs were
consistent with that required by their structures. The
structural identity of the prodrugs was then confirmed using
proton nuclear magnetic resonance (1H NMR) spectra. 1H
NMR spectra were obtained on a 300-MHz Bruker DPX300
NMR spectrometer.
30-L-Isoleucyl-FUdR: percent purity, 97%; 1H NMR
(DMSO-d6) % 0.85Y0.94 (6H, m, %CH3, "
0CH3), 1.24Y1.28
(2H, m, +CH2), 2.33Y2.51 (3H, m, C 2
0 , "CH), 3.66Y4.63 (4H, m,
C4
0 , C5
0, !CH), 5.10Y5.36 (1H, m, C3
0 ), 6.22 (1H, t, C1
0 , J = 6.1
Hz), 8.22 (1H, d, CHF, J = 7.2 Hz); ESI-MS: 360.4 (M + H)+.
50-L-Isoleucyl-FUdR: percent purity, 98%; 1H NMR
(DMSO-d6) % 0.82Y0.91 (6H, m, %CH3, "
0CH3), 1.25Y1.28
(2H,m,+CH2), 2.30Y2.50 (3H, m, C2




0, !CH), 6.15Y6.19 (1H, m, C10 ), 6.17 (1H, t, C10,
J = 6.0 Hz), 7.92 (1H, d, CHF, J = 7.2 Hz); ESI-MS: 360.4
(M + H)+.
30,50-L-Isoleucyl-FUdR: percent purity, 96%; 1H NMR
(DMSO-d6) % 0.82Y0.95 (12H, m, [%CH3]2, ["
0CH3]2),
1.24Y1.45 (4H, m, [+CH2]2), 2.30Y2.71 (4H, m, C2
0, ["CH]2),
4.04Y4.56 (5H, m, C4
0, C5
0, [!CH]2), 5.42Y5.57 (1H, m, C3
0 ),
6.22 (1H, t, C1
0, J = 6 Hz), 8.10 (1H, d, CHF, J = 6.8 Hz); ESI-
MS: 473.5 (M + H)+.
30-L-Leucyl-FUdR: percent purity, 98%; 1H NMR
(DMSO-d6) % 0.91Y0.93 (6H, m, [%CH3]2), 1.59Y1.71 (3H, m,
"CH2, +CH), 2.33Y2.35 (2H, m, C2
0 ), 3.66Y4.38 (4H, m, C4
0, C5
0,
!CH), 5.34Y5.43 (1H, m, C3
0 ), 6.24 (1H, t, C1
0, J = 6.2 Hz), 8.26
(1H, d, CHF, J = 6.5 Hz); ESI-MS: 360.4 (M + H)+.
50-L-Leucyl-FUdR: percent purity, 98%; 1H NMR
(DMSO-d6) % 0.85Y0.93 (6H, m, [%CH3]2), 1.59Y1.70 (3H, m,
"CH2, +CH), 2.14Y2.19 (2H, m, C2




0, !CH), 6.15 (1H, t, C1
0, J = 6.0 Hz), 7.93 (1H, d, CHF, J =
6.6 Hz); ESI-MS: 360.4 (M + H)+.
30,50-L-Leucyl-FUdR: percent purity, 96%; 1H NMR
(DMSO-d6) % 0.82Y0.95 (12H, m, [%CH3]4), 1.24Y1.88 (6H, m,
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["CH2]2, [+CH]2), 2.35 (2H, m, C2
0 ), 4.27Y4.56 (5H, m, C40, C50,
[!CH]2), 5.42Y5.57 (1H, m, C3
0 ), 6.22 (1H, t, C1
0, J = 6.0 Hz),
8.06 (1H, d, CHF, J = 6.6 Hz); ESI-MS: 473.5 (M + H)+.
Cell Culture
HeLa cells (passage 50Y54), and Caco-2 cells (passage
30Y35) from American Type Culture Collection (Rockville,
MD, USA) were routinely maintained in Dulbecco’s modified
Eagle’s medium containing 10% fetal bovine serum, 1%
nonessential amino acids, 1 mM sodium pyruvate, and 1%
L-glutamine. Cells were grown in an atmosphere of 5% CO2
and 90% relative humidity at 37-C.
Enzymatic Stability
Confluent Caco-2 cells were washed with phosphate-
buffered saline (pH 7.4) and then harvested with 0.05%
trypsinYEDTA at 37-C for 5Y10 min. Trypsin was neutralized
by adding Dulbecco’s modified Eagle’s medium. The cells
were washed off the plate and spun down by centrifugation.
The pelleted cells were washed twice with phosphate buffer
(10 mM, pH 7.4), and resuspended in phosphate buffer
(10 mM, pH 7.4) to obtain a final concentration of 4.7  106
cells/mL. The cells were then lysed with one volume 0.5%
Triton X-100 solution. The cells were then homogenized by
vigorous pipetting and total protein was quantified with the
BioRad DC Protein Assay using bovine serum albumin as a
standard. The hydrolysis reactions were carried out in 96-well
plates (Corning). Caco-2 cell suspension (230 2L) was placed
in triplicate wells; the reactions were started with the
addition of substrate (40 2L) and incubated at 37-C for
30Y60 min. The final prodrug concentration in the mixture
was 400 2M. At each time point, 40-2L aliquot sample was
removed and added to two volumes of 5% ice-cold TFA. The
mixtures were centrifuged for 10 min at 1,800 rcf and 4-C.
The supernatant was then filtered with a 0.45-2m filter and
analyzed via reverse-phase HPLC.
Stability in Human Plasma
The stability of the prodrugs in human plasma was
determined using the procedure below. Undiluted plasma
(230 2L) was added to each well in triplicate and 40 2L of
substrate was added to initiate the reactions, which were
conducted at 37-C for up to 3 h. At various time points,
Fig. 1. Synthesis of floxuridine ester prodrugs.
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40 2L aliquots were removed and added to two volumes
of 5% TFA. The mixtures were centrifuged for 10 min at
1,800 rcf and 4-C. The supernatant was then filtered with
a 0.45 2m filter and analyzed via reverse phase HPLC.
Chemical Stability
The degradation profiles of the prodrugs were deter-
mined in phosphate buffer (10 mM, pH 7.4) and in 4-
morpholineethanesulfonic acid (MES) buffer (10 mM, pH
6.0) alone to obtain the contribution of nonenzymatic
hydrolysis. The experiments were carried out in triplicate as
described above except that each well contained buffer
instead of cell homogenate.
[3H]Glycyl-L-Sarcosine Uptake Inhibition
HeLa cells were infected with adenovirus containing
PEPT1 as described previously (19). Two days after viral
infection the HeLa/PEPT1 cells (HeLa cells overexpressing
PEPT1) were incubated with 10 2M glycyl-L-sarcosine (9.98
2M Gly-Sar and 0.02 2M [3H]Gly-Sar) along with various
prodrug concentrations (5.0Y0.01 mM) for 30 min. The cells
were washed three times with ice-cold phosphate-buffered
saline and solubilized with 0.1% Triton X-100/0.1 N NaOH.
The suspension was then counted by scintillation counting
(Beckman LS-9000, Beckman Instruments, Fullerton, CA,
USA). IC50 values were determined using nonlinear data
fitting (Graph Pad Prism v3.0).
Uptake Studies
Carrier-mediated transport of the prodrugs was screened
in HeLa/PEPT1 cells as described previously (20). Briefly, 2
days postinfection, the cells were incubated with 0.5 mL of
freshly prepared drug solution (1 mM) in uptake buffer.
After 45 min, cells were washed with ice-cold uptake buffer
and 0.3 mL of 0.1% sodium dodecyl sulfate in water was
added to each well. The protein was precipitated from the
cell lysates by 5% TFA (final concentration) and pelleted by
centrifugation. Filtered supernatant was analyzed by HPLC
to determine prodrug/drug concentrations. Control experi-
ments were performed in normal HeLa cells.
Caco-2 Permeability
Transcellular transport studies were performed in tripli-
cate with minor modifications as described previously (21).
Uptake buffers contained 1 mM CaCl2, 1 mM MgCl2 I6H2O,
150 mM NaCl, 3 mM KCl, 1 mM NaH2PO4, 5 mM D-glucose,
and 5 mM MES or 5 mM Tris. Briefly, 3.75  105 cells were
seeded onto collagen-coated membranes (0.4-2m pore size,
12 mm diameter, Costar, Cambridge, MA, USA) and cells
were allowed to grow for 21Y26 days. Mannitol permeability
was assayed for each batch of Caco-2 monolayers (n = 3) and
TEER measurements were performed on all monolayers.
Monolayers with apparent [14C]mannitol permeability < 3 
10j7 cm/s and TEER values > 250 4/cm2 were used for the
study. 1.5 mL of prodrug solution (0.8 mM) in MES buffer
(pH 6.0) was added to the apical side of the monolayer and
2.6 mL of Tris buffer (pH 7.4) to the receiver compartment
on the basolateral side of the monolayer. Samples were taken
from both sides (200 2L from basolateral side, 20 2L from
apical side) at various time points up to 120 min. To minimize
enzymatic degradation, samples were acidified with 0.1%
TFA and stored at j80-C until HPLC analysis.
Resistance to Metabolism of Floxuridine and Its Prodrugs by
Thymidine Phosphorylase
The stability of floxuridine and its prodrugs in the
presence of thymidine phosphorylase (TP) was assessed by
incubating the desired substrates (400 2M) with TP (2 ng/2L)
in phosphate buffer (pH 6.4) at 37-C. The pyrimidine
nucleoside gemcitabine was also tested as a positive control.
Aliquots of the incubation mixture were periodically sampled
over 30 min, quenched with cold TFA (2% final), and
analyzed for prodrug, parent, and metabolite concentrations
via HPLC.
Data Analysis
The initial rates of hydrolysis were used to obtain the
apparent first-order rate constants and to calculate the half-
lives. The apparent first-order degradation rate constants of
various floxuridine prodrugs (and valacyclovir) at 37-C were
determined by plotting the logarithm of prodrug remaining as
a function of time. The slopes of these plots are related to the
rate constant, k, and given by
k ¼ 2:303 slope log C vs:timeð Þ ð1Þ
The degradation half-lives were then calculated by the
equation,
t1=2 ¼ 0:693=k ð2Þ
Statistical significance was evaluated with GraphPad
Prism v. 3.0 by performing one-way analysis of variance with
post hoc Tukey’s test to compare means.
The apparent permeability (Papp) for the prodrugs was







where Vr is the receiver volume, A is the surface area of the
exposed monolayer, C0 is the concentration of the prodrug in
the donor solution, and dCr/dt is the rate of change of
concentration in the receiver solution. The concentrations of
floxuridine and its prodrugs in the receiver and donor
compartments were analyzed using HPLC.
HPLC Analysis
The concentrations of floxuridine and its prodrugs were
determined on a Waters HPLC system (Waters Inc., Milford,
MA). The HPLC system consisted of two Waters pumps
(Model 515), a Waters autosampler (WISP model 712), and a
Waters UV detector (996 Photodiode Array Detector). The
system was controlled by Waters Millennium 32 software
(Version 3.0.1). Samples were injected onto a Waters Xterra
C18 reversed phase column (5 2m, 4.6  250 mm) equipped
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with a guard column. The HPLC and analysis methods for
floxuridine and its prodrugs and for valacyclovir were
described previously (5). Standard curves generated for each
prodrug and their parent drugs were used for quantitation of
integrated area under peaks.
RESULTS
Floxuridine Prodrug Synthesis
Amino acid ester prodrugs of floxuridine were synthe-
sized as described in Fig. 1. The TFA salts of the 30-
monoester (5aY5c), 50-monoester (6aY6c), and 30,50-diester
(7aY7c) floxuridine prodrugs were obtained as white fluffy
powders. The total prodrug yield for each amino acid was
more than 60% and the purity for all prodrugs was Q96% as
determined by HPLC. The impurities were the other isomers
and/or the parent drug. The prodrug identities were con-
firmed by ESI-MS and 1H NMR.
Stability Studies
The half-lives (t1/2), obtained from linear regression of
pseudo-first-order plots of prodrug concentration vs. time in
MES buffer (pH 6.0) and in phosphate buffer (pH 7.4) at
37-C are shown in Table I. The mass balance for prodrug
disappearance and parent drug appearance was excellent
under our HPLC analysis conditions (100 T 2%). All
prodrugs evaluated were more stable at pH 6.0 than at pH
7.4. At both acidic and neutral pH, the L-isoleucyl ester
prodrugs of floxuridine were approximately 4- to 7-fold more
stable than the L-leucyl esters, but not as stable as valacyclo-
vir. The chemical stability of the 30 and 50 monoester
prodrugs was similar; however, diester prodrugs exhibited a
2-fold lower stability compared with the monoesters.
The half-lives of the floxuridine prodrugs determined in
Caco-2 cell homogenates and in human plasma at 37-C are
also summarized in Table I. Again, isoleucyl ester prodrugs
were about 4- to 7-fold more resistant to enzymatic hydro-
lysis compared with the corresponding leucyl ester prodrug.
The enzymatic activity in Caco-2 cell homogenates was about
10-fold greater than that in human plasma and in pH 7.4
buffer. Thus, the hydrolysis rates of the isoleucyl and leucyl
floxuridine prodrugs in plasma and in phosphate buffer (pH
7.4) were similar and highly correlated (r2 = 0.95). With the
exception of leucyl prodrugs in Caco-2 cell homogenates, the
stability of the esters in buffers and in biological media were
in the order: 30 monoester Q 50 monoester 30,50 diester. Lastly,
the enzymatic stability of the isoleucyl monoester prodrugs
of floxuridine in Caco-2 cell homogenates was about 2- to
4-fold greater than that of the leucyl prodrugs and the com-
mercially marketed valacyclovir prodrug.
Uptake Inhibition Studies
The affinity of the floxuridine prodrugs for PEPT1 was
measured by the extent of Gly-Sar uptake in HeLa/PEPT1
cells. IC50 values determined in HeLa/PEPT1 cells are
presented in Table II. All prodrugs displayed increased
affinity for PEPT1 compared with floxuridine, which exhib-
ited no apparent affinity over the concentration range tested.
With the exception of the 50-L-leucyl prodrug, all floxuridine
prodrugs examined in this study exhibited IC50 values that
were similar to those obtained with valacyclovir, a well-
established PEPT1 substrate.
Direct Uptake Studies
With the exception of the diester prodrugs, the uptake of
all floxuridine prodrugs examined in this study was enhanced
Table I. Stability of Floxuridine Prodrugs in Buffers and Biological Media (Mean T SD, n = 3)
Prodrugs pH 6.0, t1/2 (min) pH 7.4, t1/2 (min) Plasma, t1/2 (min) Caco-2, t1/2 (min)
30,50-L-Leucyl floxuridine 144.6 T 2.5 40.6 T 0.3 36.8 T 1.0 8.4 T 0.6
30-L-Leucyl floxuridine 227.9 T 12.6 73.6 T 2.9 87.4 T 2.1 8.0 T 0.2
50-L-Leucyl floxuridine 225.1 T 3.8 77.3 T 1.2 57.6 T 1.4 4.8 T 0.2
30,50-L-Isoleucyl floxuridine 943.2 T 49.2 126.9 T 5.9 162.1 T 4.2 19.8 T 2.5
30-L-Isoleucyl floxuridine 1,486.3 T 25.9 333.4 T 10.3 294.1 T 9.5 28.9 T 1.9
50-L-Isoleucyl floxuridine 1,453.5 T 60.2 323.52 T 1.5 271.4 T 3.2 24.8 T 1.7
Valacyclovir 5,700a 1,029.1 T 11.2 312.0 T 2.6 10.3 T 0.8
a From Ref. (15).





(nmol /mg per 45 min)
Uptake (HeLa control)
(nmol /mg per 45 min) PEPT1/Control
30,50-L-Leucyl floxuridine 1.16 T 0.18 0.45 T 0.06 0.41 T 0.02 1.1
30-L-Leucyl floxuridine 0.74 T 0.12 1.19 T 0.11 0.54 T 0.01 2.2
50-L-Leucyl floxuridine 2.02 T 0.32 1.28 T 0.13 0.42 T 0.04 3.1
30,50-L-Isoleucyl floxuridine 0.60 T 0.10 0.42 T 0.07 0.31 T 0.06 1.3
30-L-Isoleucyl floxuridine 1.19 T 0.24 4.97 T 0.35 0.62 T 0.07 8.0
50-L-Isoleucyl floxuridine 0.86 T 0.08 5.30 T 0.26 0.50 T 0.05 10.7
50-L-Valyl floxuridine 0.97 T 0.09 3.42 T 0.09 0.18 T 0.01 19.2
Valacyclovir 1.46 T 0.36 2.83 T 0.30 0.60 T 0.05 4.7
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in HeLa/PEPT1 cells compared with uptake in HeLa cells
(Table II). The prodrug uptake enhancement ranged between
2.2- to 19.2-fold. In comparison, the transport of valacyclovir,
the reference prodrug, was 4.7-fold higher in HeLa/PEPT1
cells compared with that in control HeLa cells. PEPT1-
mediated enhancement in uptake with isoleucyl monoester
prodrugs was roughly 4-fold higher than that observed with
leucyl monoester prodrugs. For these monoester prodrugs, the
site of esterification affected PEPT1-mediated transport in a
modest manner. 50-L-Valyl floxuridine exhibited the highest
uptake enhancement. The uptake of 50-L-valyl, 30-L-isoleucyl,
and 50-L-isoleucyl floxuridine prodrugs exceeded that ob-
served with the reference prodrug valacyclovir.
Caco-2 Permeability
Apical to basolateral permeability was evaluated for
eight floxuridine prodrugs and several controls (Fig. 2). The
apparent permeability of the two pyrimidine nucleoside
drugs, gemcitabine and floxuridine, across Caco-2 mono-
layers was lower than 1  10j6 cm/s. Of the floxuridine
prodrugs tested, only the 50-L-valyl, 50-L-leucyl, 50-L-isoleucyl,
and 30-L-isoleucyl monoester prodrugs exhibited significant
enhancement compared with floxuridine. 30-L-Leucyl and 50-
L-aspartyl floxuridine, the two other monoester prodrugs
examined, exhibited permeability that was poor and similar
to that of floxuridine itself. The isoleucyl and leucyl diesters
were even less permeable than the floxuridine parent drug.
The uptake enhancement observed with HeLa/PEPT1 cells
compared with control HeLa cells for the compounds tested
(Table II) correlated highly with their permeability across
Caco-2 monolayers (r2 = 0.99) (Fig. 3).
The extent of hydrolysis of select prodrugs in Caco-2
monolayer transport experiments is summarized in Table III.
The results indicate that ester hydrolysis of the prodrugs is
not extensive when in contact with the apical side of the
monolayers (<5% at 120 min). The fate of the prodrug after
transport across the monolayers was, however, dramatically
dependent on the amino acid promoiety and its stereochem-
istry. Thus, 50-L-valyl-FUdR was extensively hydrolyzed
(õ35%), whereas its D analog exhibited much greater
stability after transport (õ15% hydrolysis). In comparison,
the hydrolysis of 50-L-isoleucyl-FUdR after transport seems
to be quite moderate (õ20%). The reference prodrug
valacylovir was extensively hydrolyzed (õ85%) after trans-
port across Caco-2 monolayers.
Thymidine Phosphorylase Activity Against Floxuridine
and Prodrugs
The metabolic stability of floxuridine and its amino ester
prodrugs was assessed using pure thymidine phosphorylase.
The results shown in Fig. 4a indicate that floxuridine was
rapidly degraded to the less active metabolite, 5-FU, by
thymidine phosphorylase. It is also evident from Fig. 4a that
an excellent mass balance between the disappearance of
floxuridine and the appearance of 5-FU is maintained at all
time points examined. The other pyrimidine nucleoside drug
gemcitabine, however, exhibited high resistance to degrada-
tion by thymidine phosphorylase to cytidine (Fig. 4b). The
amino acid ester prodrugs of floxuridine were also quite
Fig. 2. Apparent permeability coefficients (Papp) of floxuridine and
its amino ester prodrugs in the apical-to-basolateral direction across
Caco-2 monolayers (mean T SD, n = 3).
Fig. 3. Correlation of PEPT1-mediated uptake enhancement in
HeLa/PEPT1 cells with apparent apical-to-basolateral permeability
across Caco-2 monolayers.
Table III. Stability of Select Prodrugs in Caco-2 Cell Permeability







50-L-Leucyl floxuridine 92.0 T 3.0 77.0 T 1.2
50-L-Isoleucyl floxuridine 97.0 T 6.0 77.1 T 5.8
50-D-Isoleucyl floxuridine 100.0 T 1.0 99.7 T 2.5
50-L-Valyl floxuridine 75.9 T 8.1 34.7 T 3.3
50-D-Valyl floxuridine 95.3 T 2.2 83.9 T 5.7
Valacyclovir 91.3 T 2.4 15.5 T 6.0
a Percent prodrug remaining intact in donor and receiver solutions at
120 min.
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resistant to degradation by thymidine phosphorylase as
depicted for the 50-L-isoleucyl prodrug in Fig. 4c.
DISCUSSION
The development of oral alternatives to intravenous ad-
ministration of fluoropyrimidines such as floxuridine would
not only avert the high costs dictated by hospital treatments
but also be more patient-friendly. In addition, it may also be
possible to incorporate prodrug strategies that could reduce
undesirable side effects such as toxicity and improve thera-
peutic action into such oral alternatives. As a first step toward
such a realization, it would be necessary to address three key
issues that would determine overall floxuridine disposition.
The first of these involves a predictable assurance of desirable
intestinal transport characteristics. The second is the avoid-
ance or slowing of the metabolic conversion of floxuridine to
its less active metabolite, 5-FU, in the liver. Thirdly, and
possibly via a combined effect of intestinal absorption and
liver metabolism, it would be essential to maintain therapeu-
tic profiles of floxuridine that can mimic an intravenous
infusion.
In this report, we describe the synthesis of leucyl and
isoleucyl amino acid ester prodrugs of floxuridine and their
suitability as substrates of the PEPT1 intestinal transporter.
The chemical stability in buffers and enzymatic activation in
surrogate cell systems and the ability to evade extensive
metabolism by thymidine phosphorylase were also deter-
mined to identify prodrugs that could be potentially useful
for oral delivery of floxuridine.
Amino acid esters of nucleoside analogs such as acyclovir
have been designed and evaluated for their transport across
intestinal membranes (15). These studies indicated that
optimal transport occurred with valyl esters and led to the
development of valacyclovir. The enhanced oral bioavailabil-
ity of valacyclovir in humans (22) has been suggested to be
the result of enhanced intestinal transport by peptide trans-
port systems (16,23,24). Consistent with previous findings,
50-L-valyl floxuridine was the most efficiently transported
floxuridine prodrug, exhibiting the highest PEPT1-mediated
transport and permeability across Caco-2 monolayers (15,25).
In comparison, the slightly more branched isoleucyl side
chain reduced the transport almost by half. In addition, it
seems that branching at the + carbon in leucine chains as
opposed to branching at the " carbon in isoleucine and valine
decreases the transport efficiency even further. The lack of
direct uptake despite the significant inhibition of Gly-Sar
transport by the diesters suggests uptake inhibition studies
alone may not be sufficient.
The transport of floxuridine, a hydrophilic drug, across
Caco-2 monolayers was limited but not insignificant. Although
floxuridine is not expected to be passively transported, it is
quite likely that they are actively transported via pyrimidine
nucleoside transporters such as CNT2 (5,26). The permeabil-
ity of 50 monoester prodrugs of floxuridine across Caco-2
monolayers was significantly higher than that of floxuridine
itself and reflected a profound promoiety dependency. Thus,
the permeability of the 50-L-valyl prodrug was roughly 2- and
5-fold higher than the permeability of the 50-L-isoleucyl and
50-L-leucyl floxuridine prodrugs, respectively. This trend is
consistent with their PEPT1-mediated uptake enhancement
in HeLa cells and resembles the trends reported for amino
acid ester prodrugs of acyclovir in rats (15). The poor
permeability of 50-L-aspartyl floxuridine across Caco-2 mono-
layers is consistent with previous reports that suggest that this
prodrug is not a substrate of PEPT1 (6,24). The enhanced
transport of the 30-L-isoleucyl floxuridine prodrug across
Caco-2 cells comparable to its 50 analogue is in contrast to
the behavior of 30-L-leucyl floxuridine, which exhibited a 2-
fold lower transport compared with 50-L-leucyl floxuridine.
The excellent linear correlation between uptake en-
hancement of the amino acid ester prodrugs in HeLa cells
mediated by PEPT1 and AP-BL permeability across Caco-2
monolayers (r2 = 0.99) indicates the high likelihood of their
Fig. 4. Thymidine phosphorylase activity against nucleosides.
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active transport in Caco-2 cells as well. The overlay of
the reference prodrug valacyclovir on this correlation plot
and the observation that the 50-L-isoleucyl and 50-L-valyl
floxuridine prodrugs both exhibit substantially higher Caco-2
permeability than valacyclovir provide some assurance that
these two prodrugs may indeed exhibit enhanced in vivo
intestinal transport.
Although Caco-2 cells are used as a model for human
intestine, they lack expression of many metabolizing
enzymes found in the intestine. Caco-2 cells do not express
thymidine or uridine phosphorylase; however, high levels
of both are expressed in the intestine (27). Thymidine
phosphorylase, an enzyme that has been suggested to be
important in vivo for phosphorytic cleavage of floxuridine
(28), was therefore used to examine metabolism by nucleo-
side phosphorylases that would normally be observed in the
intestine and liver. As expected, floxuridine was rapidly
cleaved by thymidine phosphorylase in this study, whereas
the other pyrimidine nucleoside analog, gemcitabine, resisted
breakdown. It has been proposed that the mechanism of
thymidine phosphorylase-catalyzed cleavage of pyrimidine
nucleosides involves the initial attack of a phosphate ion on
the C10 position of the sugar moiety that leads to glycosidic
bond cleavage (29). The attachment of two fluorine groups at
the adjacent C20 position of the sugar moiety in gemcitabine
may prevent the initial phosphate ion attack on the C10
position and obviate thymidine phosphorylase catalytic
action. All amino acid ester prodrugs examined in this study
were stable to glycosidic bond cleavage by thymidine
phosphorylase. Thus, the chemical modification of floxur-
idine by esterification of one or both of the free hydroxyl
groups on the sugar moiety seems to provide protection from
glycosidic bond cleavage. Structural studies with purine
nucleoside phosphorylase revealed that these hydroxyl
groups are critical for efficient substrate binding (30), which
suggests that it may also be important for pyrimidine
nucleoside phophorylases. Enzymatic activation of the pro-
drug via ester hydrolysis would therefore deprotect it from
thymidine phosphorylase action. Thus, the rate of bioactiva-
tion of the amino acid ester prodrugs of floxuridine is likely
the rate-limiting step to glycosidic bond cleavage of floxur-
idine to 5-FU. Thus, the rate of conversion of the prodrugs to
the parent drug after transport would determine floxuridine
disposition and therapeutic action.
The roughly 5- to 12-fold higher activity in Caco-2 cell
homogenates compared with pH 7.4 buffer suggests the
predominance of enzymatic bioconversion of the prodrugs.
The stability profiles of leucyl ester prodrugs of floxuridine
in Caco-2 cell homogenates (and in human plasma)
indicate that they would not be suitable candidates. In
comparison, isoleucyl ester prodrugs of floxuridine are
enzymatically more stable than the valyl ester floxuridine
prodrugs previously investigated (5) and also more stable
than the reference prodrug valacyclovir. The preference for
50 monoesters over the corresponding 30 monoester is
consistent with the trends reported for activation of amino
acid ester prodrugs of floxuridine and gemcitabine by
biphenyl hydrolase-like protein (BPHL) or valacyclovirase,
an enzyme responsible for activation of valacyclovir and
amino acid ester prodrugs (31) and by carboxylesterase
(Landowski et al., unpublished data). It has been suggested
that 30 floxuridine esters exhibit higher antitumor effect
than 50 esters partly due to their enhanced enzymatic sta-
bility (32,33).
Furthermore, assessment of the basolateral compart-
ment at 2 h (Table III) indicates that around 77% of 50-L-
isoleucyl-FUdR remains intact after passage across Caco-2
monolayers. In comparison, only 15% of the reference
prodrug valacyclovir, and 35% of 50-L-valyl-FUdR were
found as intact prodrug in the basolateral compartment at
2 h. Thus, it seems that at least in the Caco-2 model, ester
hydrolysis of 50-L-isoleucyl-FUdR was not extensive. It is
quite possible that the extent of ester hydrolysis in vivo after
transport across the human intestine (and in liver) may be
higher than that predicted with the Caco-2 model. In this
regard, we have compared the hydrolysis kinetics of amino
acid ester prodrugs by BPHL and by carboxylesterase, both
of which are highly expressed in the human liver and
intestine. The results (Landowski et al., unpublished data)
indicated that 50-L-isoleucyl-containing prodrugs are poor
substrates for both BPHL and carboxylesterase. Accordingly,
the BPHL specific activity toward 50-L-isoleucyl-FUdR was
found to be 15- to 20-fold lower than that observed with two
very good BPHL substrates, valacyclovir and 50-L-valyl-
FUdR. Carboxylesterase 1 catalytic activity toward 50-L-valyl
and 50-L-isoleucyl-FUdR was even lower than that obtained
with BPHL. These data indicate that ester bond hydrolysis,
especially with 50-L-isoleucyl floxuridine, may be limited in
vivo. However, in vivo experiments with the floxuridine
prodrugs would be necessary to determine the actual
combined metabolism effects of the intestine and liver.
The combined results of the in vitro studies suggest that
isoleucyl monoesters of floxuridine may be potentially
promising candidates for improving oral bioavailability of
floxuridine in vivo. The prodrugs given orally could
improve the intestinal uptake of floxuridine as well as
shield it from unwanted degradation. Although the 50-L-
valyl floxuridine prodrug may be transported to a much
greater extent across the intestine, its more rapid activation
in vivo may not be beneficial in evading metabolism by
thymidine phosphorylase. Rapid intestinal activation is also
expected to lead to increased intestinal toxicity. The dispo-
sition of floxuridine after oral administration of the candidate
prodrugs in mice will be determined to corroborate some of
these indications.
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